Patterns of disability, care needs, and quality of life of people with Parkinson’s disease in a general population sample

2012 ◽  
Vol 18 (7) ◽  
pp. 828-832 ◽  
Author(s):  
D.L. Terriff ◽  
J.V.A. Williams ◽  
S.B. Patten ◽  
D.H. Lavorato ◽  
A.G.M. Bulloch
2010 ◽  
Vol 120 (1-3) ◽  
pp. 126-132 ◽  
Author(s):  
Mascha C. ten Doesschate ◽  
Maarten W.J. Koeter ◽  
Claudi L.H. Bockting ◽  
Aart H. Schene

2011 ◽  
Vol 20 (7) ◽  
pp. 1123-1129 ◽  
Author(s):  
Luciane N. Cruz ◽  
Carisi A. Polanczyk ◽  
Suzi A. Camey ◽  
Juliana F. Hoffmann ◽  
Marcelo P. Fleck

2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Jonathan Mond ◽  
Deborah Mitchison ◽  
Janet Latner ◽  
Phillipa Hay ◽  
Cathy Owen ◽  
...  

2008 ◽  
Vol 10 (5) ◽  
pp. 625-634 ◽  
Author(s):  
Luis Gutirrez-Rojas ◽  
Manuel Gurpegui ◽  
Jos L Ayuso-Mateos ◽  
Jos A Gutirrez-Ariza ◽  
Miguel Ruiz-Veguilla ◽  
...  

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Kim Rand ◽  
Espen Ajo Arnevik ◽  
Espen Walderhaug

Abstract Purpose There is a need to assess the quality of treatment for Substance Use Disorder (SUD), and document SUD patients’ health-related quality of life (HRQoL). The study aims to describe Norwegian SUD patients’ HRQoL as measured by EQ-5D, compared to a general population sample, and discuss the potential usefulness of the EQ-5D to monitor HRQoL for SUD patients. Methods One hundred seventy eight SUD patients (66.3% male) were administered the EQ-5D-3L at treatment start. Patients and general population samples were compared in terms of reported EQ-5D-3L health states, problems by dimension, UK index values, and EQ VAS scores. We investigated specific drug dependence, mental health disorders, sex, age, and education as predictors of EQ-5D-3L values and EQ VAS scores. Anxiety/depression dimension scores were compared to Hopkins symptom Checklist (HSCL-25) scores. Results 91.6% of the patient sample reported problems on the EQ-5D-3L, with 29.8% reporting extreme problem, compared to 39.8% and 3.0% in the general population sample. Mean index (EQ VAS) score among SUD patients was .59 (59.9) compared to .90 (84.1) in the general population. Regression analyses identified phobic anxiety and cocaine dependence as statistically significant predictors of higher EQ-5D-3L index scores. Conclusion SUD patients report substantially reduced HRQoL, as measured using the EQ-5D-3L. The most frequently reported problems were for the anxiety/depression, pain/discomfort, and usual activities dimensions. The EQ-5D may be a useful and practical instrument for monitoring HRQoL in SUD patients.


2008 ◽  
Vol 102 (3) ◽  
pp. 399-406 ◽  
Author(s):  
Marianne Voll-Aanerud ◽  
Tomas M.L. Eagan ◽  
Tore Wentzel-Larsen ◽  
Amund Gulsvik ◽  
Per S. Bakke

Sleep Science ◽  
2019 ◽  
Vol 12 (2) ◽  
Author(s):  
Camila Hirotsu ◽  
Cristina Frange ◽  
Patricia H Hirata ◽  
Renata C Cremaschi ◽  
Fernando M Coelho ◽  
...  

2009 ◽  
Vol 160 (1) ◽  
pp. 17-24 ◽  
Author(s):  
Joern Moock ◽  
Christin Albrecht ◽  
Nele Friedrich ◽  
Henry Völzke ◽  
Matthias Nauck ◽  
...  

ObjectiveTo analyse 12-month response to GH treatment in a single-country cohort of hypopituitary adult patients with GH deficiency (GHD) in regards to health-related quality of life (HRQoL) and insulin-like growth factor-1 (IGF-1) compared with values from general population sample. Moreover, association between the response in HRQoL and the IGF-1 values in patients and in the background population was investigated.DesignHRQoL was assessed by quality of life assessment of GH deficiency in adults (QoL-AGHDA) in 651 patients retrieved from the German KIMS (Pfizer International Metabolic Database) before and after 12 months of GH replacement and in a sample drawn from a cross-sectional study in Germany (n=2734). IGF-1 was measured in KIMS patients and in the population-based study with the same assay technique.ResultsIn KIMS patients, mean QoL-AGHDA scores before GH replacement were 9.2±6.8 (8.7±6.8) in women (men) and in the general population sample 4.5±5.3 (4.3±5.0) in women (men). Mean differences in QoL-AGHDA scores were statistically significant for all age categories (P<0.05). The mean IGF-1 SDS of KIMS patients before GH replacement was −1.1±1.4 (−0.8±1.4) in women (men). After GH replacement, a significant increase of IGF-1 concentration and a significant decrease of QoL-AGHDA scores near to age- and gender-specific population-based values were observed.ConclusionsThis study confirms an improvement in HRQoL and an increase of IGF-1 SDS in GH-replaced adults, which approximated the values of general population. However, there was no association between IGF-1 values and HRQoL assessment as one of the important treatment outcomes.


Sign in / Sign up

Export Citation Format

Share Document